Company intelligence / Profile preview
Odonate Therapeutics
New York, New York, United Statesodonate.com ↗
- Ownership
- Private
- Employees
- ~46
- Development stage
- Other
01
Overview
Odonate Therapeutics was a pharmaceutical company focused on developing tesetaxel, an orally administered taxane chemotherapy agent for the treatment of metastatic breast cancer. The company discontinued development and began winding down operations in March 2021 after FDA feedback indicated its clinical data package was unlikely to support approval[8].
- Therapeutic areas
- Oncology
- Modalities
- Small molecules (specifically taxanes/chemotherapy agents)
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Odonate Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Odonate Therapeutics.